First, fecal GUSB activity and tissue n-6/n-3 ratio could be utilized as biomarkers to micro-type patients with cancer receiving Irinotecan and improving its pharmacokinetics or reducing its toxicity. The gene discussed is GUSB; the disease is cancer.